Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial.

Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial. - SkinHeRo

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033409

Enrollment

Registered

2018-07-17

Start date

2018-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Pretreatment by heparinoid In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients diagnosed as Parkinson's disease 2. patients without severe dementia

Exclusion criteria

Exclusion criteria: 1. severe dementia 2. severe skin disease 3. severe allergic reactions to rotigotine or heparinoid 4. patients who are judged as not suitable for participation in this study

Design outcomes

Primary

Measure	Time frame
The difference in the 4-week change in Skindex 16 between the pretreatment group and the non-pretreatment group	—

Secondary

Measure	Time frame
The difference in the 1-week and 8-week change in Skindex 16. Skindex 16 score, DLQI score, UPDRS part3, PDQ-39, amount of heparinoid used, drop out rate (due to or not due to local skin reaction), dosage of rotigotine, at week 1, 4, and 8.	—

Countries

Japan

Contacts

Public ContactJinsoo Koh

Wakayama Medical University Department of Neurology

jinsoo@wakayama-med.ac.jp073-441-0655

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026